Skip to main content

Table 2 Baseline characteristics of the study population (n = 19)

From: A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

Characteristic Value
Age, years, median (range) 60 (34–86)
Performance status, n
 0 9
 1 9
 2 1
Measurable disease, n (%) 16 (84)
Prior therapy, n
 Chemotherapy 17
 Hormonal therapy 7
 HER-2 inhibitor 18
 Radiotherapy 15
ER-positive, n (%) 10 (53%)
HER-2 positive, n (%) 19 (100%)
Number of sites of disease, n (%)
 1 5 (26%)
 2 2 (11%)
 3 6 (32%)
 ≥4 6 (32%)
Site of disease, n (%)
 Bone 9 (47%)
 Soft tissue 10 (53%)
 Brain 2 (11%)
 Lung/liver 16 (84%)
  1. n number of patients, HER-2 human epidermal growth factor receptor 2, ER estrogen receptor